CoChat
Sign Up
Cited by 368Acute Lymphoblastic Leukemia researchHistorical Medical Research and TreatmentsLymphoma Diagnosis and Treatment

A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia

Open access
Pui, Ching-Hon, Evans, William E.·2013·Seminars in Hematology
DOI 10.1053/j.seminhematol.2013.06.007PMC PMC3771494
Open this paper in CoChat — free account

Abstract

The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children's Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups, and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.seminhematol.2013.06.007

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ALL treatment has changed dramatically since older survivors were diagnosed, with cranial radiation therapy almost entirely replaced by chemotherapy-only protocols.

    “ALL treatment has changed dramatically since these older survivors were diagnosed (Pui & Evans, 2013; Simone, 2006): due to concerns of significant neuropsychological effects (Janzen & Spiegler, 2008; Spiegler et al., 2006), cranial radiation therapy has almost entirely been replaced by chemotherapy‐only protocols (Pui & Evans, 2013; Pui et al., 2009).”

    From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Pui & Evans, 2013

  • Incidence of ALL is higher in boys than in girls, and boys require longer treatment than girls due to sex-specific risk factors for ALL relapse.

    “Secondly, sex modulates disease‐ and treatment‐specific factors: incidence of ALL is higher in boys than in girls (Inaba et al., 2013; National Cancer Institute 2015; Pui & Evans, 2013; Pui et al., 1999; Sather, Miller, Nesbit, Heyn, & Hammond, 1981), and boys require longer treatment (~2.5 years) than girls (~2 years) due to sex‐specific risk factors for ALL relapse (Brecher et al., 1986; Tiedem”

    From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Pui & Evans, 2013

    Pui and Evans (2013) is cited for the higher incidence of ALL in boys; the separate claim about treatment duration has different citations. The passages from Precise risk stratification and Host pharmacokinetics, pharmacodynamics and pharmacogenetics discuss prognosis and incidence by racial or ethnic group, but not incidence by sex. Searches for boys, girls, male, and male predominance found no passage addressing the cited comparison. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 103

  1. [1]Farber S Diamond LK Mercer RD Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid 374 N Engl J Med 1948 238 787 93 18860765
  2. [3]Pinkel D Five-year follow-up of “total therapy” of childhood lymphocytic leukemia JAMA 1971 216 648 52 5279904
  3. [4]Aur RJ Simone J Hustu HO Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia Blood 1971 37 272 81 4322483
  4. [5]Henze G Langermann HJ Brämswig J The BFM 76/79 acute lymphoblastic leukemia therapy study (author’s transl) Klin Padiatr 1981 193 145 54 6943387
  5. [6]Sallan SE Hitchcock-Bryan S Gelber R Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia Cancer Res 1983 43 5601 7 6352020
  6. [7]Sullivan MP Chen T Dyment PG Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study Blood 1982 60 948 58 6956376
  7. [8]Freeman AI Weinberg V Brecher ML Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children N Engl J Med 1983 308 477 84 6571946
  8. [9]Jones B Freeman AI Shuster JJ Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia Med Pediatr Oncol 1991 19 269 75 2056971
  9. [10]Pui CH Campana D Pei D Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med 2009 360 2730 41 19553647 PMC2754320
  10. [11]Evans WE Crom WR Abromowitch M Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect N Engl J Med 1986 314 471 7 3456079
  11. [12]Evans WE Relling MV Rodman JH Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia New Engl J Med 1998 338 499 505 9468466
  12. [13]Krynetski EY Schuetz JD Galpin AK A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase Proc Natl, Acad Sci 1995 92 949 53 7862671 PMC42614
  13. [14]Schultz KR Bowman WP Aledo A Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study J Clin Oncol 2009 27 5175 81 19805687 PMC2773475
  14. [15]Ford CE Jacobs PA Lajtha LG Human Somatic Chromosomes Nature 1958 181 1565 68 13566072
  15. [16]Propp S Lizzi FA Philadelphia chromosome in acute lymphoblastic leukemia Blood 1970 36 353 360 5271290
  16. [17]Secker-Walker LM Lawler SD Hardisty RM Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis Br Med J 1978 2 1529 1530 281981 PMC1608754
  17. [18]Williams DL Look AT Melvin SL New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia Cell 1984 36 101 109 6607116
  18. [19]Borella L Sen L T cell surface markers on lymphoblasts from acute lymphoblastic leukemia J Immunol 1973 111 1257 1260 4580669
  19. [20]Kirsch IR Morton CC Nakahara K Leder P Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes Science 1982 216 301 303 6801764
  20. [21]Croce CM Isobe M Palumbo A Gene for 3-chain of human T-Cell receptor: location on chromosome 14 region involved in T-Cell neoplasms Science 1985 227 1044 1047 3919442
  21. [22]Bradstock KF Janossy G Tidman N Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia Leuk Res 1981 5 301 309 7026903
  22. [23]Yeoh EJ Ross ME Shurtleff SA Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Cancer Cell 2002 1 133 143 12086872
  23. [24]Mullighan CG Goorha S Radtke I Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia Nature 2007 446 758 764 17344859
  24. [26]Treviño LR Yang W French D Germline genomic variants associated with childhood acute lymphoblastic leukemia Nat Genet 2009 41 1001 1005 19684603 PMC2762391
  25. [27]Papaemmanuil E Hosking FJ Vijayakrishnan J Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia Nat Genet 2009 41 1006 1010 19684604 PMC4915548
  26. [28]Möricke A Zimmermann M Reiter A Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 Leukemia 2010 24 265 284 20010625
  27. [29]Hunger SP Lu X Devidas M Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group J Clin Oncol 2012 30 1663 1669 22412151 PMC3383113
  28. [30]Veerman AJ Kamps WA van den Berg H Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004) Lancet Oncol 2009 10 957 966 19747876
  29. [31]Vrooman LM Stevenson KE Supko JG Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00–01 J Clin Oncol 2013 31 1202 1210 23358966 PMC3595424
  30. [32]Yamaji K Okamoto T Yokota S Watanabe A Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group Pediatr Blood Cancer 2010 55 1287 95 20535816
  31. [33]Yeoh AE Ariffin H Chai EL Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study J Clin Oncol 2012 30 2384 2392 22614971
  32. [34]Vora A Goulden N Wade R Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial Lancet Oncol 2013 14 199 209 23395119
  33. [35]Schmiegelow K Forestier E Hellebostad M Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia Leukemia 2010 24 345 354 20010622
  34. [36]Downing JR Wilson RK Zhang J The Pediatric Cancer Genome Project Nat Genet 2012 44 619 622 22641210 PMC3619412
  35. [37]Pui CH Mullighan CG Evans WE Relling MV Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012 120 1165 174 22730540 PMC3418713
  36. [38]Coustan-Smith E Mullighan CG Onciu M Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Lancet Oncol 2009 10 147 156 19147408 PMC2840241
  37. [39]Chen B Wang YY Shen Y Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with reports from Western countries Leukemia 2012 26 1608 1616 22382891
  38. [40]Pui CH Relling MV Downing JR Acute lymphoblastic leukemia N Engl J Med 2004 350 1535 1548 15071128
  39. [41]Mullighan CG Collins-Underwood JR Phillips LA Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia Nat Genet 2009 41 1243 1246 19838194 PMC2783810
  40. [42]Chen IM Harvey RC Mullighan CG Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study Blood 2012 119 3512 3522 22368272 PMC3325039
  41. [44]Den Boer ML van Slegtenhorst M De Menezes RX A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study Lancet Oncol 2009 10 125 134 19138562 PMC2707020
  42. [45]Roberts KG Morin RD Zhang J Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia Cancer Cell 2012 22 153 166 22897847 PMC3422513
  43. [46]Holmfeldt L Wei L Diaz-Flores E The genomic landscape of hypodiploid acute lymphoblastic leukemia Nat Genet 2013 45 242 252 23334668 PMC3919793
  44. [47]Relling MV Hancock ML Rivera GK Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus J Natl Cancer Inst 1999 91 2001 2008 10580024
  45. [48]Cheok MH Evans WE Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy Nat Rev Cancer 2006 6 117 129 16491071
  46. [49]Crews KR Hicks JK Pui CH Pharmacogenomics and individualized medicine: translating science into practice Clin Pharmacol Ther 2012 92 467 75 22948889 PMC3589526
  47. [50]Yang JJ Cheng C Yang W Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia JAMA 2009 301 393 403 19176441 PMC2664534
  48. [51]Ramsey LB Panetta JC Smith C Genome-wide study of methotrexate clearance replicates SLCO1B1 Blood 2013 121 898 904 23233662 PMC3567337
  49. [52]Xu H Cheng C Devidas M ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia J Clin Oncol 2012 30 751 757 22291082 PMC3295551
  50. [53]Xu H Yang W Perez-Andreu V Novel susceptibility variants at 10p12.31–12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations J Natl Cancer Inst 2013 105 733 742 23512250 PMC3691938
  51. [54]Vogelstein B Papadopoulos N Velculescu Cancer genome landscapes Science 2013 339 1546 1558 23539594 PMC3749880
  52. [55]Pui CH Pei D Campana D Improved prognosis for older adolescents with acute lymphoblastic leukemia J Clin Oncol 2011 29 386 391 21172890 PMC3058285
  53. [56]Pui CH Pei D Pappo AS Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children’s Research Hospital, 1992 Through 2007 J Clin Oncol 2012 30 2005 2012 22547602 PMC3383176
  54. [57]Yang JJ Cheng C Devidas M Ancestry and Pharmacogenomics of Relapse in Acute Lymphoblastic Leukemia Nat Genet 2011 43 237 241 21297632 PMC3104508
  55. [58]Moorman AV Ensor HM Richards SM Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial Lancet Oncol 2010 11 429 438 20409752
  56. [59]Schrappe M Valsecchi MG Bartram CR Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Blood 2011 118 2077 2084 21719599
  57. [60]Schrappe M Hunger SP Pui CH Outcome after induction failure in childhood acute lymphoblastic leukemia N Eng J Med 2012 366 1371 1381 PMC3374496 22494120
  58. [61]Faham M Zheng J Moorhead M Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia Blood 2012 120 5173 5180 23074282 PMC3537310
  59. [62]Stow P Key L Chen X Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia Blood 2010 115 4657 4663 20304809 PMC2890183
  60. [63]Inaba H Pui CH Glucocorticoid use in acute lymphoblastic leukemia Lancet Oncol 2010 11 1096 1106 20947430 PMC3309707
  61. [64]Hunger SP Loh ML Whitlock JA Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia Pediatr Blood Cancer 2013 60 957 963 23255467 PMC4045498
  62. [65]Pieters R Schrappe M De Lorenzo P A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial Lancet 2007 370 240 250 17658395
  63. [66]Pichler H Reismüller B Steiner M The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate - a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group Br J Haematol 2013 161 556 65 23480776
  64. [67]Buitenkamp TD Pieters R Gallimore NE Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations Leukemia 2012 26 2204 2211 22441210
  65. [68]Coustan-Smith E Ribeiro RC Stow P A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Blood 2006 108 97 102 16537802 PMC1895825
  66. [69]Mikkelsen TS Sparreboom A Cheng C Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial J Clin Oncol 2011 29 1771 1778 21444869 PMC3107765
  67. [70]Asselin BL Devidas M Wang C Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404) Blood 2011 118 874 883 21474675 PMC3292437
  68. [71]Bhojwani D Pei D Sandlund JT ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy Leukemia 2012 26 265 270 21869842 PMC3345278
  69. [72]Kawedia JD Liu C Pei D Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia Blood 2012 119 1658 1664 22117041 PMC3286344
  70. [73]Seibel NL Steinherz PG Sather HN Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group Blood 2008 111 2548 2555 18039957 PMC2254538
  71. [74]Gaynon PS Angiolillo AL Carroll WL Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report Leukemia 2010 24 285 297 20016531 PMC2906139
  72. [75]Matloub Y Bostrom BC Hunger SP Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group Blood 2011 118 243 251 21562038 PMC3138679
  73. [77]Liu C Kawedia JD Cheng C Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia Leukemia 2012 26 2303 2309 22484422 PMC3516853
  74. [78]Kawedia JD Liu C Pei D Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia Blood 2012 119 1658 1664 22117041 PMC3286344
  75. [79]Pui CH Reducing delayed intensification therapy in childhood ALL Lancet Oncol 2013 14 178 179 23402706
  76. [80]Relling MV Gardner EE Sandborn WJ Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing Clin Pharmacol Ther 2011 89 387 391 21270794 PMC3098761
  77. [81]Bhatia S Landier W Shangguan M Non-adherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: A Report from the Children’s Oncology Group J Clin Oncol 2012 30 2094 2101 22564992 PMC3601449
  78. [82]Pui CH Howard SC Current management and challenges of malignant disease in the CNS in paediatric leukaemia Lancet Oncol 2008 9 257 268 18308251
  79. [83]Matloub Y Lindemulder S Gaynon PS Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children’s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children’s Oncology Group Blood 2006 108 1165 1173 16609069 PMC1895867
  80. [84]Richards S Pui CH Gaynon P Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG) Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukaemia Pediatr Blood Cancer 2013 60 185 195 22693038 PMC3461084
  81. [85]Jansen NC Kingma A Schuitema A Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia J Clin Oncol 2008 26 3025 3030 18565888
  82. [86]Conklin HM Krull KR Reddick WE Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia J Natl Cancer Inst 2012 104 1386 1395 22927505 PMC3529594
  83. [87]Schrappe M Reiter A Ludwig WD Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group Blood 2000 95 3310 3322 10828010
  84. [88]Pui CH Schrappe M Masera G Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop Leukemia 2004 18 1043 1053 15085155
  85. [89]Hunger SP Baruchel A Biondi A The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011 Pediatr Blood Cancer 2013 60 344 348 23024117
  86. [90]Evans WE Crews KR Pui CH A Health-Care System Perspective on Implementing Genomic Medicine: Pediatric Acute Lymphoblastic Leukemia as a Paradigm Clin Pharmacol Ther 2013 1 17 10.1038/clpt.2013.9 [Epub ahead of print] PMC3720796 23462885 · DOI
  87. [91]Pui CH Carroll WL Meshinchi S Arceci RJ Biology, risk stratification, and therapy of pediatric acute leukemias: an update J Clin Oncol 2011 29 551 565 21220611 PMC3071256
  88. [92]Panetta JC Gajjar A Hijiya N Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia Clin Pharmacol Ther 2009 86 651 658 19741605 PMC2831746
  89. [93]O’Brien S Schiller G Lister J High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia J Clin Oncol 2013 31 676 683 23169518 PMC4979201
  90. [94]Jeha S Gaynon PS Razzouk BI Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia J Clin Oncol 2006 24 1917 1923 16622268
  91. [95]Dunsmore KP Devidas M Linda SB Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group J Clin Oncol 2012 30 2753 2759 22734022 PMC3402886
  92. [96]Kantarjian H Thomas D Wayne AS Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia J Clin Oncol 2012 30 3876 3883 22891271 PMC3478578
  93. [97]Kantarjian H Thomas D Jorgensen J Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol 2012 13 403 411 22357140
  94. [98]Handgretinger R Zugmaier G Henze G Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia Leukemia 2011 25 181 184 20944674
  95. [99]Herrera L Bostrom B Gore L A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia J Pediatr Hematol Oncol 2009 31 936 941 19875969
  96. [100]Grupp SA Kalos M Barrett D Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 2013 368 1509 1518 23527958 PMC4058440
  97. [101]Shimasaki N Fujisaki H Cho D A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies Cytotherapy 2012 14 830 840 22458956
  98. [102]Schultz KR Bowman WP Aledo A Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study J Clin Oncol 2009 27 5175 5181 19805687 PMC2773475
  99. [103]Aplenc R Blaney SM Strauss LC Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children’s oncology group phase I consortium J Clin Oncol 2011 29 839 844 21263099 PMC3068059
  100. [104]Messinger YH Gaynon PS Sposto R Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Blood 2012 120 285 290 22653976
  101. [105]Maude SL Tasian SK Vincent T Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia Blood 2012 120 3510 3518 22955920 PMC3482861
  102. [106]Bhojwani D Pui CH Relapsed childhood acute lymphoblastic leukaemia Lancet Oncol 2013 14 e205 e217 23639321
  103. [107]Sherborne AL Hosking FJ Prasad RB Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk Nat Genet 2010 42 492 494 20453839 PMC3434228

Cited by

Sorted by citations

Authors
Pui, C.-H., & Evans, W. E.
Affiliations
St. Jude Children's Research Hospital (US)
Corresponding author
Pui, Ching-Hon
ORCID
Venue
Seminars in Hematology
Publisher
Elsevier BV
Published
2013-07
Volume
50
Issue
3
Pages
185-196
ISSN
0037-1963 (ISSN-L)
DOI
10.1053/j.seminhematol.2013.06.007
PMC
PMC3771494
OpenAlex
W2095746088
Cited by
368
References
3
Citations by year
2026: 10 · 2025: 31 · 2024: 38 · 2023: 27 · 2022: 40 · 2021: 38 · 2020: 42 · 2019: 30 · 2018: 19 · 2017: 19 · 2016: 30 · 2015: 27 · 2014: 14 · 2013: 2 · 2012: 1
FWCI
24.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Seminars in Hematology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (CA 36401, R01CA036401, CA21765, R37CA036401, P30CA021765)
  • National Institute of General Medical Sciences (U01GM092666, GM 92666)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Historical Medical Research and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
childhood acute lymphoblastic leukemia, leukemia cure, St. Jude Children's Research Hospital, cytotoxic chemotherapy, immunotherapy, pediatric oncology
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Risk Factors, Treatment Outcome, Genomics, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review